PL2104682T3 - Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych - Google Patents

Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych

Info

Publication number
PL2104682T3
PL2104682T3 PL08719192T PL08719192T PL2104682T3 PL 2104682 T3 PL2104682 T3 PL 2104682T3 PL 08719192 T PL08719192 T PL 08719192T PL 08719192 T PL08719192 T PL 08719192T PL 2104682 T3 PL2104682 T3 PL 2104682T3
Authority
PL
Poland
Prior art keywords
alzheimer
diagnosis
treatment
neurodementing
diseases
Prior art date
Application number
PL08719192T
Other languages
English (en)
Inventor
Richard Dodel
Michael Bacher
Michael Przybylski
Raluca Stefanescu
Marilena Manea
Original Assignee
Michael Bacher
Dodel, Richhard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07000507A external-priority patent/EP1944314A1/en
Priority claimed from EP07000521A external-priority patent/EP1944315A1/en
Application filed by Michael Bacher, Dodel, Richhard filed Critical Michael Bacher
Publication of PL2104682T3 publication Critical patent/PL2104682T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL08719192T 2007-01-11 2008-01-11 Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych PL2104682T3 (pl)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US88452607P 2007-01-11 2007-01-11
US88451307P 2007-01-11 2007-01-11
EP07000507A EP1944314A1 (en) 2007-01-11 2007-01-11 Diagnosis of Alzheimer's disease and other neurodementing disorders
EP07000521A EP1944315A1 (en) 2007-01-11 2007-01-11 Prophylaxis and therapy of alzheimer's disease and other neurodementing diseases
US98167507P 2007-10-22 2007-10-22
US98166707P 2007-10-22 2007-10-22
EP07119002 2007-10-22
EP07119026 2007-10-22

Publications (1)

Publication Number Publication Date
PL2104682T3 true PL2104682T3 (pl) 2017-03-31

Family

ID=39609117

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08719192T PL2104682T3 (pl) 2007-01-11 2008-01-11 Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych

Country Status (11)

Country Link
US (3) US7939075B2 (pl)
EP (1) EP2104682B1 (pl)
JP (1) JP2010515717A (pl)
AU (1) AU2008204335B2 (pl)
CA (1) CA2675340C (pl)
DK (1) DK2104682T3 (pl)
ES (1) ES2610474T3 (pl)
PL (1) PL2104682T3 (pl)
SI (1) SI2104682T1 (pl)
TW (1) TW200844110A (pl)
WO (1) WO2008084402A2 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090280114A1 (en) * 2002-04-12 2009-11-12 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
CA2628703C (en) 2005-11-30 2019-10-29 Abbott Laboratories Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EP2143447A1 (en) * 2008-07-11 2010-01-13 Universität Konstanz Bioconjugates comprising Aß-autoantibody-specific epitopes for active immunotherapy and diagnosis of Alzheimer's disease
DK3395372T3 (da) * 2009-02-20 2022-04-19 Enhanx Biopharm Inc System til afgivelse af glutathion-baseret medikament
KR101095630B1 (ko) * 2009-06-17 2011-12-19 주식회사 이노파마스크린 베타 아밀로이드 펩타이드와 ｖｅｇｆ의 상호작용을 억제하는 물질을 탐색 방법 및 그에 의해서 탐색된 저해제
DE102009034119A1 (de) * 2009-07-20 2011-01-27 Philipps-Universität Marburg Verfahren, insbesondere Enzyme-linked Immunosorbent Assay (ELISA), zum in vitro Nachweis von Amyloid beta Autoantikörpern, Mikrotiterplatte und Testkit
EP3296295A1 (en) 2009-08-07 2018-03-21 American Life Science Pharmaceuticals, Inc. Compositions and methods for treating beta-amyloid related diseases
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
ES2496341T3 (es) * 2011-10-04 2014-09-18 Affiris Ag Procedimiento para detectar anticuerpos Aß-específicos en una muestra biológica
KR101190573B1 (ko) * 2011-10-07 2012-10-18 대한민국 혈액 내 아밀로이드-베타 항체에 특이적으로 결합하는 신규 Ａβ２２（ｐＥ）－４２ 펩티드를 유효성분으로 포함하는 치매 진단용 키트
US20130273574A1 (en) * 2012-03-13 2013-10-17 Janssen Alzheimer Immunotherapy Oligomeric a-beta in the diagnosis, prognosis, and monitoring of alzheimer's disease
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
JP6582995B2 (ja) * 2014-01-21 2019-10-02 株式会社島津製作所 Ａｐｐ切断型ペプチドの測定方法
CA2973508C (en) * 2014-02-14 2022-05-17 Ruhr-Universitat Bochum Biosensor for conformation and secondary structure analysis
US10035823B2 (en) * 2014-09-29 2018-07-31 The Regents Of The University Of California Compositions for expanding regulatory T cells (TREG), and treating autoimmune and inflammatory diseases and conditions
EP3043354B1 (en) * 2015-01-12 2018-01-03 Heraeus Deutschland GmbH & Co. KG Use of an electrically conductive composition as an electrically conductive adhesive for mechanically and electrically connecting electrical conductors to electrical contacts of solar cells
EP3324186B1 (en) 2016-11-21 2020-09-16 Ruhr-Universität Bochum Method for the preselection of drugs for protein misfolding diseases
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
US11773171B2 (en) * 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
EP4603508A3 (en) 2017-12-19 2025-10-29 Surrozen Operating, Inc. Anti-frizzled antibodies and methods of use
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND USES THEREOF
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
KR20230109668A (ko) 2020-11-16 2023-07-20 서로젠 오퍼레이팅, 인크. 간-특이적 Wnt 신호 증강 분자 및 그의 용도
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
WO2025059487A2 (en) 2023-09-15 2025-03-20 Othair Prothena Limited Cell penetrating agents and uses thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
ATE239797T1 (de) * 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1998044955A1 (en) 1997-04-09 1998-10-15 Mindset Ltd. Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
ES2275570T3 (es) 1999-12-08 2007-06-16 Intellect Neurosciences, Inc. Peptidos amiloides beta quimericos.
US20020182660A1 (en) 2000-02-18 2002-12-05 Fong Kei-Lai L. N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43)
WO2001062801A2 (en) 2000-02-24 2001-08-30 Washington University Humanized antibodies that sequester amyloid beta peptide
US20030083277A1 (en) 2000-02-24 2003-05-01 Hersh Louis B. Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients
KR20060088905A (ko) * 2000-06-16 2006-08-07 휴먼 게놈 사이언시즈, 인코포레이티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
US20020009445A1 (en) 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
EP1172378A1 (en) 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
JP4317010B2 (ja) 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
US20030082191A1 (en) 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders
US20050208050A1 (en) * 2001-11-09 2005-09-22 Gerd Multhaup Compounds for the diagnosis/prevention/treatment of alzheimer's disease
WO2003051374A2 (en) 2001-12-17 2003-06-26 New York State Office Of Mental Health SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2003250102B2 (en) 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
ATE506072T1 (de) 2002-09-12 2011-05-15 Univ California Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz
CA2501091A1 (en) 2002-10-01 2004-04-15 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
CA2501945A1 (en) 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
US20050106626A1 (en) 2002-10-20 2005-05-19 George Pieczenik Ligand binding of amyloid peptide protein epitope
NZ540555A (en) * 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
WO2004056318A2 (en) 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2005025616A1 (ja) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited 抗体の用途
EP1660533A4 (en) 2003-09-12 2009-10-21 Univ California MONOCLONAL ANTIBODIES SPECIFIC TO HIGH MOLECULAR WEIGHT AGGREGATION INTERMEDIATES COMMON TO AMYLOIDS FORMED FROM PROTEINS OF DIFFERENT SEQUENCE
EP2343318A3 (en) * 2003-11-28 2013-02-27 MedImmune Limited Antibodies binding to a C-terminal fragment of apolipoprotein E
ES2375627T3 (es) 2004-02-23 2012-03-02 Eli Lilly And Company Anticuerpos anti-abeta.
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US20080287309A1 (en) 2004-07-10 2008-11-20 Alexion Pharmaceuticals, Inc. Methods for Discovering Antibodies Specific to Cancer Cells and Antibodies Discovered Thereby
US20080107601A1 (en) 2004-10-13 2008-05-08 Ablynx N.V. Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease
US20080044356A1 (en) 2004-10-22 2008-02-21 Regents Of The University Of Minnesota Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof
US7780963B2 (en) 2004-10-25 2010-08-24 Merck & Co., Inc. Anti-ADDL antibodies and uses thereof
PE20061401A1 (es) * 2004-12-15 2006-12-23 Neuralab Ltd ANTICUERPOS Aß PARA MEJORAR LA COGNICION
US20080267971A1 (en) * 2004-12-21 2008-10-30 Green Larry L Antibodies Directed to Angiopoietin-2 and Uses Thereof
WO2006081171A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
JP2008528638A (ja) 2005-01-28 2008-07-31 ワイス ポリペプチドの安定化液体処方
EP2204381A1 (en) 2005-03-05 2010-07-07 Abbott GmbH & Co. KG Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
ES2318918B1 (es) 2005-04-01 2010-02-16 Biotherapix Molecular Medicines, S.L.U. Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones.
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
WO2007062088A1 (en) 2005-11-22 2007-05-31 The Trustees Of The University Of Pennsylvania Antibody treatment of alzheimer's and related diseases
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
MX358175B (es) 2005-12-12 2018-08-08 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
RS51723B2 (sr) 2006-03-23 2018-03-30 Bioarctic Neuroscience Ab Poboljšana antitela selektivna za protofibrile i njihova primena
AU2008206923A1 (en) * 2007-01-17 2008-07-24 Merck Serono S.A. Process for the purification of Fc-containing proteins
WO2009099176A1 (ja) * 2008-02-08 2009-08-13 Immunas Pharma, Inc. Aβオリゴマーに特異的に結合する抗体およびその利用

Also Published As

Publication number Publication date
US20120039897A1 (en) 2012-02-16
US20120040382A1 (en) 2012-02-16
EP2104682B1 (en) 2016-09-21
US7939075B2 (en) 2011-05-10
AU2008204335B2 (en) 2013-06-13
CA2675340C (en) 2018-07-31
WO2008084402A3 (en) 2009-04-09
WO2008084402A2 (en) 2008-07-17
CA2675340A1 (en) 2008-07-17
US20090028869A1 (en) 2009-01-29
DK2104682T3 (en) 2017-01-16
JP2010515717A (ja) 2010-05-13
US8491903B2 (en) 2013-07-23
WO2008084402A8 (en) 2009-08-27
EP2104682A2 (en) 2009-09-30
ES2610474T3 (es) 2017-04-27
AU2008204335A1 (en) 2008-07-17
TW200844110A (en) 2008-11-16
SI2104682T1 (sl) 2017-05-31

Similar Documents

Publication Publication Date Title
PL2104682T3 (pl) Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych
IL208926A0 (en) Use of epothelone d in treating tau-associated diseases including alzheimer's disease
EP2429992A4 (en) TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER
EP2369017B8 (en) Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases
ZA200801511B (en) Novel diazaspiroalkanes and their use for treatment of CCR8 medicated diseases
EP2152318A4 (en) COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
EP2091566A4 (en) COMBINATION THERAPIES AGAINST ALZHEIMER DISEASE AND SIMILAR ILLNESSES
EP2151435A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
PL2056842T3 (pl) Modyfikowany galaktozyloceramid do leczenia chorób nowotworowych
PT2056863T (pt) Tratamento de doenças oculares
EP2306824A4 (en) IONTOPHORETIC DELIVERY OF CURCUMINE AND CURCUMINANALOGUE FOR THE TREATMENT OF MORBUS ALZHEIMER
EP2051732A4 (en) DIAGNOSIS AND TREATMENT OF METABOLIC DISORDERS AND METHODS THEREFOR
PL1981515T3 (pl) Leczenie urazów i chorób mózgu za pomocą MAPC
EP2568811A4 (en) TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER
EP2206714A4 (en) AGENT FOR THE PREVENTION AND / OR TREATMENT OF SKIN DISEASES
EP2320939A4 (en) TISSUE CALLICLE FOR THE TREATMENT OF PARKINSON DISEASE
WO2010105035A9 (en) Prevention, treatment, and diagnosis of alzheimer's disease through electromagnetic field exposure
IL213703A (en) Compounds for the treatment of pain and other diseases
IL186022A0 (en) Dermatological compositions and salts for the treatment of dermatological diseases
GB0608647D0 (en) Methods of diagnosis and treatment
EP1773882A4 (en) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH SIGLEC-6
ZA200904755B (en) Use of epothilones in the treatment of osteoporosis and related diseases
PL2307380T3 (pl) Pochodne N’-nitroksyalkilonikotynamidu do leczenia chorób układu sercowo-naczyniowego
EP2099476A4 (en) METHODS OF TREATING ALZHEIMER'S DISEASE
EP1846013A4 (en) TREATMENT OF SKIN DISEASES